Bradykinesia as a Digital Biomarker

Bradykinesia is slowness of movement together with progressive reduction in speed or amplitude as a movement is repeated. It is the cardinal feature required for a diagnosis of parkinsonism, and it is assessed clinically by asking a person to perform repetitive tasks such as finger tapping or hand opening and closing while a clinician grades what they see.

Digital measurement decomposes that judgement into its parts. Sensors quantify the speed of each repetition, its amplitude, the rhythm between repetitions, and the sequence effect, meaning the progressive decay that distinguishes bradykinesia from simple slowness. Those components can move independently, and separating them gives a richer description than a single ordinal grade.

The term also carries a consumer trap. Searches for it are dominated by general interest, and this page is written for the clinical research context rather than the symptom checker one.

Two approaches are used. Structured task measurement asks the person to perform a defined movement while wearing a sensor, or to tap on a screen, and derives speed, amplitude and decrement from the recording. This mirrors the clinical examination and is what most validation work has used. Passive measurement estimates bradykinesia from ordinary movement across the day without asking for a task, which trades precision for coverage.

Validation has compared sensor derived scores with modified clinical rating approaches, showing that kinematic measures track clinician grading while providing continuous resolution. Tap based tests deserve particular attention because the sequence effect, the decay across repetitions, is a specific marker that a simple speed measurement misses and that dedicated tap tests are designed to capture.

The main use is quantifying motor state and its response to treatment. Because bradykinesia fluctuates with medication, repeated measurement across a day describes the dosing cycle rather than a single point in it, which is what titration decisions actually need.

In trials, sensor derived motor scores are used as supporting endpoints alongside the standard clinical rating scale, and as a way of collecting motor data between site visits. Home based tap tests have been evaluated for reliability against clinic assessment, which supports their use for remote monitoring.

Measures are reported alongside the Nine Hole Peg Test, which is the closest clinic equivalent for upper limb dexterity, and alongside disease stage and quality of life instruments that describe what the slowness costs.

Task based measures depend on effort and cooperation, which is the same weakness they were meant to remove. A person having a bad day, or one who does not understand the instruction, produces a score that reflects the circumstance rather than the disease.

Passive estimates avoid that but are confounded by everything else that slows movement, including fatigue, pain, arthritis, low mood and simply not being in a hurry. Cross device comparison is unreliable because the task, sampling rate and derived score differ. And the reference standard is a clinician's ordinal judgement, which means validation is measured against something less precise than the measure itself, a circularity worth naming.

• Heldman DA, et al. The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. Mov Disord. 2011. pubmed.ncbi.nlm.nih.gov
• Hasan H, et al. Technologies assessing limb bradykinesia in Parkinson's disease. J Parkinsons Dis. 2017. pubmed.ncbi.nlm.nih.gov
• Heldman DA, et al. App-based bradykinesia tasks for clinic and home assessment in Parkinson's disease: reliability and validity. J Parkinsons Dis. 2017. pubmed.ncbi.nlm.nih.gov
• Artusi CA, et al. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinsonism Relat Disord. 2018. pubmed.ncbi.nlm.nih.gov